78 results about "Glycolipid metabolism" patented technology

The invention relates to a probiotic composition, and discloses a probiotic composition beneficial for a glycolipid metabolic function and a preparation and application of the composition. The probiotic composition comprises some of the following nine probiotics: bifidobacterium longum, bifidobacterium breve, lactobacillus gasseri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus crispatus, lactobacillus plantarum, lactobacillus fermentum and lactobacillus casei. Different strains in the probiotic composition cooperate with each other, so that the probiotic composition has thefunction of adjusting glycolipid metabolism, and has certain effect on serum total cholesterol, triglycerides, insulin beta-cell functions and diabetes mellitus improvement.

The present invention provides a FGF21 and IGF-1 fusion protein, wherein fusion is performed through an appropriate linker peptide fragment in an optimal fusion manner, and the produced fusion proteinsuccessfully retains the respective biological activities. According to the present invention, specifically the fusion protein sequentially contains human fibroblast growth factor-21 (hFGF21), a flexible peptide linker (L), a human immunoglobulin Fc fragment, a flexible peptide linker (L) and an insulin-like growth factor (IGF-1) from the N terminal to the C terminal; and the fusion protein provides high regulation effect in glycolipid metabolism and the like compared to the single use of the proteins, enhances the treatment effects on metabolic disorders, cardiovascular diseases, liver fat lesions and other diseases, and overcomes the side effects (such as osteoporosis, cancer risk and the like).

The invention discloses a chicken forage containing a raw material acanthopanax senticosus. The chicken forage is prepared from the following raw materials in percent by weight: 300-450 parts of corn, 100-120 parts of soybean meal, 60-80 parts of sorghum, 50-60 parts of wheat middling, 30-40 parts of rice bran, 20-30 parts of shell powder, 20-30 parts of pieris rapae powder, 40-50 parts of sweet potato powder, 10-15 parts of garlic, 12-15 parts of black fungus, 10-15 parts of mulberry leaf powder, 8-10 parts of lotus root starch, 10-15 parts of acanthopanax senticosus and 4-5 parst of a feeding promoting agent. Acanthopanax senticosus contains a large amount of biological activity factors, and is capable of enhancing body immunization capability, improving body circulation environment, balancing glycolipid metabolism; superoxide dismutase SOD compound contained in acanthopanax senticosus has extremely good antioxidation capability; and additionally, acanthopanax senticosus is abundant in vitamins, mineral matters and multiple amino acid, is capable of well supplementing nutrition of the forage, improving production performance of egg-laying chicken, laying rate of the egg-laying chicken and the weight of laid eggs, and prolonging egg-laying period as well as enhancing immunization capability.

The invention provides a Chinese medicinal preparation for treating diabetes, which is prepared from heterophylly falsestarwort root, gypsum, Indian buead, pollen, dwarf lilyturf tuber, cochinchnese asparagus root, chicken gizzard-membrane, tortoise plastron, dendrobium, turtle shell, medlar, cinnamomvine, common macrocarpium fruit, villous amomum fruit, root of rehmannia, Chinese magnoliavine fruit, dark plum fruit, pangolin, root of straight ladybell, fragrant solomonseal rhizome, common anemarrhena rhizome, dragon's bones and oyster shell according to a conventional Chinese medicament preparation process. The preparation is a pure Chinese medicinal preparation, is used for the treatment of the diabetes and complicating diseases thereof, and has the advantages of having steady therapeutic effect, having no toxic side effect, adjusting the environment in organisms, improving the constitution, relieving the state of insulin resistance, adjusting glycolipid metabolism, strengthening glucose homeostasis and the like.

The invention relates to the field of medicine biology, wherein a liver-specific MEN1 gene knocked out mouse model is established to research effects of menin in liver cells, and results show that MEN1 gene provides important effects in EMT inhibition (epithelial-mesenchymal transition of liver cells) and glycolipid metabolism regulation. In addition, the MEN1 gene can be adopted for preparing and screening anti-hepatic fibrosis and anti-fatty liver drugs so as to provide valuable clues and directions for clinical targeted therapy.

An application of the extract of persimmon leaf in ethyl acetate in preparing the medicines to prevent and treat the diseases associate with glycolipid metabolism (such as hyperglycemia, diabetes, hyperlipemia, and hypertension) and metabolism syndrome is disclosed.

The invention relates to animal feed, and discloses nutritional special food beneficial to weight loss of obese sterile cats and a preparation method thereof. The nutritional special food comprises 2-8 parts of quinoa, 15-25 parts of chicken meal, 18-26 parts of fish meal, 1-5 parts of fish oil, 3-8 parts of rapeseed oil, 3-8 parts of fruits and vegetables, 18-26 parts of starch, 1-5 parts of beeryeast powder, 0.1-0.5 part of taurine, 0.01-0.05 part of L-carnitine, 1-5 parts of a premix, 8-15 parts of soybean protein concentrate and 2-6 parts of a pet feed compound seasoning. According to thespecial nutritional food, the intake of proteins and dietary fibers is increased, the intestinal digestive function and muscle growth of the sterile cats are promoted, and meanwhile, the intake of fat and sugar is reduced, so that the special nutritional food plays a beneficial role in glycolipid metabolism of the sterile cats, and further is beneficial to weight loss of the obese sterile cats.

The invention relates to an application of bile acid to preparation of a metabolic disease drug. DCA (deoxycholic acid), GDCA (glycodeoxycholic acid) and TDCA (taurodeoxycholic acid) can increase basic metabolism rate by increasing the steatolysis and oxidation functions of white adipose tissues, in-vivo glycolipid metabolism is improved, intestinal flora are adjusted, high fat induced mouse obesity is relieved, and the application has great significance for clinically translational target spot search.

The invention discloses a healthy solid beverage and a preparation method thereof. The beverage comprises the following raw material components in parts by weight: 10-50 parts of hawthorn extract, 5-20 parts of kudzuvine root extract, 2.5-20 parts of chitosan oligosaccharide, 2-20 parts of mulberry leaf extract, 1-20 parts of chrysanthemum extract, 1-20 parts of cassia seed extract, 1-15 parts ofwater-soluble dietary fiber, 0.5-8 parts of erythritol, 2-10 parts of apple extract and 10-20 parts of oat extract. The preparation method comprises the following steps: squeezing hawthorns / apples into juice, diluting and filtering the juice to obtain extract, grinding kudzu vine roots / oat into powder, adding water, conducting extraction to obtain extract, adding water into mulberry leaves / chrysanthemums / cassia seeds, conducting extraction to obtain extract, adding chitosan oligosaccharide, water-soluble dietary fiber and erythritol into the mixture of the extract, and conducting stirring, concentrating, and spray-drying to obtain the product. The healthy solid beverage disclosed by the invention is appropriate in taste and flavor, obviously improves glycolipid metabolism disorder of a human body, and has health-care and immunity-improving effects; and the production process is simple and easy for personnel operation and large-scale popularization.

The invention belongs to the technical field of medicines, and particularly relates to application of pectolinarin in preparation of a medicine for treating glycolipid metabolism diseases and a medicinal composition. According to the application of the pectolinarin in preparation of the medicine for treating the glycolipid metabolism diseases, experiments prove that the pectolinarin has the effects of reducing blood sugar of mice suffering from glycolipid metabolism disorder, regulating blood fat, reducing weight and reducing abdominal girth, can also promote L cells of intestinal tracts of the mice to secrete hypoglycemic hormone GLP-1 to achieve the effect of enhancing the insulin sensitivity, and can effectively treat the glycolipid metabolism diseases. The invention also provides the medicinal composition containing the pectolinarin. The medicinal composition comprises the pectolinarin and atractylenolide I. Compared with the pectolinarin, the medicinal composition has the advantages that the blood sugar is reduced, the blood fat is regulated, the effect of promoting the intestinal L cells to secrete the hypoglycemic hormone GLP-1 is more remarkable, and the medicinal composition has a good application prospect in the aspect of treating the glycolipid metabolism diseases.

The invention discloses a method for establishing an insulin resistance animal model. According to the method, feed with high content of selenium, sugar and fat and low-concentration fructose drinkingwater are used for inducing inbred line C57BL / 6 mice with highly similar genetic backgrounds in order to cause glycolipid metabolism disorder of the mice and then induce the occurrence of insulin resistance, and then the insulin resistance animal model is established. Through unique proportioning of the feed, a pathogenesis process of the insulin resistance caused by the change of a dietary structure is highly simulated, comparison between the induced animal model and a control group shows that animals in a model group are obviously different from animals in the normal control group in intakeglucose tolerance, insulin tolerance, animal insulin resistance index and insulin sensitivity index, and it is indicated that the animals in the model group have obvious insulin resistance. The method has the advantages that the special feed is adopted for feeding in two modes, adverse reactions caused by chemical reagents are eliminated, a molding method is simple, the molding rate is high, thecost is low, and the reproducibility is high.

The invention discloses a preparation method of synbiotic, which uses mulberry leaves as raw materials, then hydrolyzing with hemicellulase, carrying out nanofiltration, ultrafiltration and column chromatography purification to obtain mulberry leaf oligosaccharide, enriching intestinal flora with glycolipid metabolism regulation activity by using the mulberry leaf oligosaccharide as a carbon source, and carrying out separation to obtain the most obviously enriched strain; and finally, co-culturing the purified mulberry leaf oligosaccharide and the enriched strain obtained by separation to prepare the synbiotic rich in mulberry leaf oligosaccharide and strain. The preparation method of the synbiotic is simple, and the prepared synbiotic can effectively regulate and control the glycolipid metabolism activity.

The invention relates to a traditional Chinese medicine composition for improving glycolipid metabolism of diabetes mellitus and application thereof. The traditional Chinese medicine composition is prepared from the following bulk drugs in parts by weight: 9 parts of radix puerariae, 9 parts of radix astragali, 6 parts of radix codonopsis, 6 parts of rhizoma atractylodis macrocephalae, 6 parts ofporia cocos, 3 parts of liquorice root, 6 parts of radix ophiopogonis and 6 parts of perilla frutescens. The traditional Chinese medicine composition has the advantages that the bulk drugs and the weight ratio thereof are optimized, and the kudzuvine root in the formula is sweet and spicy in taste and mild in nature, enters the spleen and the stomach, and can clear yang, promote salivation, quenchthirst, relieve muscles and dredge collaterals; radix astragali is sweet in taste, slightly warm in nature and capable of tonifying spleen, lung and primordial qi, and the kudzuvine root and radix astragali jointly achieve the effects of tonifying qi, promoting salivation and tonifying spleen and serve as monarch drugs. Radix codonopsis is sweet in taste and mild in nature, and has the effects oftonifying qi and spleen, nourishing blood and engendering liquid; rhizoma atractylodis macrocephalae is bitter and warm, and has the effects of invigorating spleen, drying dampness and strengtheningmiddle-jiao transportation; the poria cocos is sweet in taste, tonifying spleen and excreting dampness, the radix codonopsis, rhizoma atractylodis macrocephalae and poria cocos are matched and have effects of tonifying spleen, reducing phlegm and clearing damp, and the three drugs are minister drugs. Radix ophiopogonis is sweet, slightly bitter and slightly cold and can nourish yin and promote salivation; perilla frutescens leaves are warm in nature, spicy in taste, capable of promoting qi circulation, harmonizing stomach, helping digestion and removing food stagnation, and radix ophiopogonisand perilla frutescens are adjuvant medicines together. The raw liquorice has the effects of tonifying qi, harmonizing the middle warmer and harmonizing the drugs to serve as conductant drugs.

The invention discloses a construction method of plasmids for interfering pig CRTC3 gene expression. The method comprises the following steps: designing and obtaining three target sequences accordingto the information of a pig CRTC3 gene sequence and a carrier, and designing and synthesizing three pairs of shRNA (1-3) primers of pig CRTC3 according to the target sequences; and connecting annealing products of the three pairs of shRNA (1-3) primers of the pig CRTC3 with pAdM-FH-GFP carriers subjected to BamH I and Hind III enzyme digestion and carrying out conversion to obtain pAdM-FH-GFP-sh(1-3)-CRTC3 recombinant plasmids. The invention further provides an application of the pAdM-FH-GFP-sh1-CRTC3 plasmids and adenoviruses of the pig CRTC3: knocking out the expression of the CRTC3 gene inpig intramuscular fat and subcutaneous fat cells and researching the influence generated by pig glycolipid metabolism and related gene expression and the like.

The invention relates to low-GI total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on a ketogenesis principle and application of the low-GI total-nutrient meal replacement powder. The meal replacement powder is prepared from the following raw materials: freshly squeezed coconut oil, conjugated linoleic acid glyceride, linseed oil, olive oil, fish oil, high oleic acid sunflower seed oil, soybean oil, whey protein concentrate, soy isolate protein, hydrolyzed fish collagen, casein, rice protein, quinoa flour, chia seeds, konjac powder, inulin, fructo-oligosaccharide, L-carnitine, glutamine, enzymes, vitamin complex and mineral complex. The formula has the advantages that the energy supply ratio of the three nutrients is as follows: 70%-75% of fat, 3%-5% of carbohydrate and 20%-27% of protein. By utilizing the characteristics that MCT (medium-chain fatty acid) does not store fat and can quickly supply energy to a human body, insulin resistance is reduced, glycolipid metabolism disorder is improved, and the purpose of reducing weight is achieved. A scientific and convenient ketogenic diet replacement scheme is provided, and the ketogenic diet replacement scheme is convenient to implement and popularize in crowds.

The invention relates to use of a mulberry extract in preparation of a medicine for treating abnormal glycolipid metabolism and diseases caused by abnormal glycolipid metabolism in mammals, which is characterized in that the plant extract is prepared according to the following steps of: (1), preparing crude extract; (2), separating by cationic resin and / or optional anionic resin; (3), performing alcohol precipitation treatment on the resin effluent in the step (2); and, an optional step (4), performing concentration and drying. The mulberry extract in the invention can obviously reduce the glycosylated hemoglobin and the blood fat concentration of the type 2 diabetes KK-Ay mouse; simultaneously, the safety is high; and the good treatment effect is provided for the type 2 diabetes and the related complications, such as dyslipidemia.

The invention discloses a follow-up visit management system of malignant tumor combined with diabetes mellitus based on a cloud APP, and the system comprises a cloud management platform which comprises a patient end and a doctor end; wherein the patient end comprises a personal information module, a disease knowledge module, a patient data monitoring module and a patient-doctor communication module; the doctor end comprises a patient filing module, an information publishing module, a doctor-patient communication module, a doctor data monitoring module and a management platform application, andthe management platform application comprises management group training, learning effect assessment and follow-up visit management. The management platform suitable for patients with esophageal squamous cell carcinoma complicated with diabetes mellitus is developed by applying an internet technology and a WeChat platform, and carries out scientific management on indexes such as blood sugar leveland glycolipid metabolism of the patients in the perioperative period and within one year after the patients are taken out of hospital, so as to form a set of scientific and feasible esophageal squamous cell carcinoma complicated with diabetes mellitus management mode based on mobile internet. And improvement of operation quality and prognosis of a patient is promoted.

The invention relates to the technical field of medicines, in particular to a Tmem52 protein for regulating glycolipid metabolism, a coding gene and application of the Tmem52 protein. The amino acid sequence of the Tmem52 protein disclosed by the invention is as shown in SEQ ID NO. 1. According to the invention, C57BL6 / n wild mice fed with high-fat feed are taken as research objects, and the weight of the mice can be obviously reduced by utilizing the Tmem52 protein preparation provided by the invention, so that the Tmem52 protein provided by the invention can be used for treating obesity and related diseases by regulating abnormal glucose and lipid metabolism.

The invention discloses a lactobacillus reuteri bacterium agent for improving utilization of high-sugar feed of pelteobagrus fulvidraco and a preparation method thereof. The lactobacillus reuteri bacterium agent with high content of reuterin, which is disclosed by the invention, contains high content of reuterin; and compared to a conventional lactobacillus reuteri bacterium agent (which does notcontain high content of reuterin), the combination of high content of reuterin and lactobacillus reuteri can further improve the growth performance and the feed utilization rate of the pelteobagrus fulvidraco, obviously improve the glycolipid metabolism capability and the immunity, and reduce the occurrence of diseases. Therefore, according to the invention, by exogenously adding the lactobacillusreuteri bacterium agent with high content of reuterin, which is disclosed by the invention, into a high-sugar feed, feed utilization can be improved, the glycolipid metabolism of the pelteobagrus fulvidraco is effectively promoted, abdominal cavity lipopexia is reduced, occurrence of the fatty liver is reduced, non-specific immunity of the pelteobagrus fulvidraco is improved, and occurrence of diseases is reduced.

The invention belongs to the technical field of biological medicines, and particularly relates to application of glucosamine in preparation of a medicine for treating non-alcoholic fatty liver disease. Experiments prove that the glucosamine with the daily dose of 300-600 mg / kg can improve insulin resistance, glycolipid metabolism disorder and liver lipid accumulation of mice with the non-alcoholicfatty liver disease, improve liver dysfunction, enhance oxidation resistance, and reduce body inflammation and serum endotoxin level. Therefore, the glucosamine has a certain treatment effect on thenon-alcoholic fatty liver disease.

The invention discloses Application of sodium houttuyfonate in preparation of products for prevention and treatment of diabetic cardiopathy. Houttuyfonate sodium can be use for preparing product for preventing and treating diabetic heart disease, regulating myocardial energy metabolism disorder, and improving glycolipid metabolism abnormality. The invention has been proved by experiments that: (1)sodium houttuyfonate has preventive and therapeutic effects on diabetic heart disease and cardioprotective effects; (2) It can regulate the disturbance of myocardial energy metabolism; (3) It can reduce the increase of blood lipid caused by diabetes mellitus and has the effect of lowering blood glucose. It has good clinical application prospect in the prevention and treatment of diabetes-inducedcardiac injury, myocardial energy metabolism disorder, glucose and lipid metabolism abnormalities and so on.

Methods of detecting novel therapeutically active compositions based on their ability to modulate the glycolipid metabolism and overcome multidrug resistance are described. These methods are particularly useful in screening for novel chemotherapeutic agents for the treatment of cancer, as well as chemosensitizers that are capable of enhancing the cytotoxicity of such chemotherapeutic agents. A combination of one or more of these compositions can be used in the treatment of a various cancers.

The invention discloses a Chinese herbal compound for reducing weight and lowering lipid as well as a preparation method and application of the Chinese herbal compound. The Chinese herbal compound forreducing weight and lowering lipid is prepared from the following raw materials in parts by mass: 5-50 parts of fructus mume, 5-50 parts of Chinese dwarf cherry seed, 5-50 parts of fructus gardeniae,5-50 parts of semen cassiae, 5-50 parts of rhizoma curcumae longae and 5-50 parts of lotus leaf. The Chinese herbal compound for reducing weight and lowering lipid and the preparation method of the Chinese herbal compound have the beneficial effects that the Chinese herbal compound has good effects of reducing weight and lowering lipid, controlling weight, regulating glycolipid metabolism and improving insulin resistance, and is low in adverse response and low in price; in view of the deficiencies of traditional extraction and separation methods, a Chinese herbal compound combination with a specific ratio is optimized by means of the uniform design of system conditions aiming at the special properties of effective components of the raw material medicines of the Chinese herbal compound provided by the invention; furthermore, a supercritical carbon dioxide fluid extraction technology with proper conditions is explored to extract the effective components; the supercritical carbon dioxidefluid extraction technology is less in used organic solvents, high in extraction efficiency and separation efficiency, strong in operability and low in production cost, thus being suitable for large-scale production.

The present invention provides an application of a pharmaceutical composition containing hydroxyurea, and hydroxyurea or pharmaceutically acceptable salts thereof are used for preparation of medicinesfor preventing and / or treating atherosclerosis. The results of an experiment show that after oral administration of combination of hydroxyurea, aspirin and clopidogrel hydrogen sulfate, aortic intimafat and porridge-like lesion regions are significantly reduced, the drug effect on atherosclerosis is obvious (plaque inhibition degree 85%), the concentration of blood glucose, triglyceride, total cholesterol, low-density lipoprotein cholesterol is decreased, and glycolipid metabolism disorder is significantly improved; after oral administration of combination of hydroxyurea, aspirin, clopidogrel hydrogen sulfate and atorvastatin calcium, aortic intima fat and porridge-like lesion regions are significantly reduced, and atherosclerosis is essentially cured (plaque inhibition degree 91%). Thecombination of drugs at this dose has an outstanding therapeutic effect in the prevention and / or treatment of atherosclerosis.

The invention discloses an application of CGP 57380 in preparation of a medicine for preventing and treating type 2 diabetes. CGP 57380 is a cell-permeable pyrazole-pyrimidine compound, and it is found that CGP 57380 can relieve hyperglycemia and hyperinsulinemia of high-fat-induced type 2 diabetic mice and improve the glucose tolerance level and insulin sensitivity of high-fat mice by inhibiting the kinase activity and protein expression quantity of BRSK2, and finally, the glycolipid metabolism disorder of the high-fat mice is remarkably improved, the effect of treating the type 2 diabetes is achieved, and an important reference value is provided for clinical research and development of new drugs.

The invention relates to the technical field of animal model establishment, in particular to a non-alcoholic fatty liver animal model and an establishment method. The animal model is established by adopting an NR4A1- / -gene knockout mouse. The NR4A1- / -gene knockout mouse is adopted to establish the non-alcoholic fatty liver animal model, the relationship between the NR4A1- / -gene and glycometabolism and fat metabolism of the liver is fully utilized, the glycolipid metabolism of the NR4A1- / -gene knockout mouse is disturbed, and fat can be deposited on the liver after high-fat feeding, so that the non-alcoholic fatty liver is formed; the method is simple to operate and obvious in effect. The animal model has the characteristics of obesity, dyslipidemia and the like, and has high similarity with NAFLD clinical pathology.

The invention discloses an application of GGPP combined and allosteric activated human FBP1 in preparation of a medicine for resisting hepatocellular carcinoma. The amino acid sequence of the human FBP1 protein is as shown in SEQ ID No.1. According to the application of GGPP combined and allosteric activated human FBP1 in preparation of the medicine for resisting hepatocellular carcinoma, a direct binding protein action network of GGPP in normal liver is established, and a plurality of GGPP binding proteins participating in liver glycolipid metabolism regulation are screened and verified. The GGPP is specifically combined with the FBP1, the enzyme activity of the FBP1 is up-regulated, gluconeogenesis is promoted, and migration of parenchymal liver cells and liver cancer cells can be inhibited. The GGPP sensitizes the target protein FBP1 of the GGPP to couple glycolipid metabolism balance so as to regulate the molecular mechanism of hepatocellular carcinoma generation and development, and can be applied to treatment of hepatocellular carcinoma. GGPP is directly combined with the specificity of the target protein FBP1 to regulate and control the glycolipid metabolism balance of the liver, and a novel potential target, a novel medicine and a novel treatment method are provided for treatment of HCC.

The invention belongs to the technical field of medicines, and relates to a 90% methanol extract prepared from branches and leaves of Pseudotsuga sinensis, labdane and abietane diterpenoid compounds separated from the methanol extract, a preparation method of the compounds and application of the compounds in pharmacy. A biological activity test shows that the compound remarkably inhibits ATP-citrate lyase (ACL); the compound can be used for preparing medicines or lead compounds of the medicines for preventing or treating ACL-mediated glycolipid metabolism disorder related diseases, such as hyperlipemia, atherosclerosis, non-alcoholic fatty liver disease, type 2 diabetes mellitus and obesity.